Abingworth
VC Fund
London, United Kingdom
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.
- Total investments:
- 173
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $356M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Abingworth invests in
Stages Abingworth invests in
Countries Abingworth invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $14M–$115M
- Series B
- $18M–$95M
- Series C
- $20M–$120M
Investment Focus
Industry
- Biotechnology 87 (50%)
- Health Care 58 (34%)
- Pharmaceutical 40 (23%)
- Medical 33 (19%)
- Therapeutics 27 (16%)
Stage
- Series B 38 (22%)
- Series A 34 (20%)
- Series C 25 (14%)
- Funding Round 18 (10%)
- Post-IPO Equity 17 (10%)
Country
- United States 66 (38%)
- United Kingdom 17 (10%)
- France 5 (3%)
- Switzerland 5 (3%)
- Sweden 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Gallagher
Partner
|
Partner | Total investments: 8 | Find email | |
John Shields
Advisor, Science and Technology
|
Advisor, Science and Technology | Total investments: 1 | Find email | |
Quentin Lloyd-Harris
Partner
|
Partner | Total investments: 9 | Find email | |
Alex Asquith
General Counsel and Chief Financial Officer
|
General Counsel and Chief Financial Officer | Total investments: 0 | Find email | |
Andrew Sinclair
Partner & Portfolio Manager
|
Partner & Portfolio Manager | Total investments: 4 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
cAMPfield Therapeutics
|
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M / Series A / May 20, 2026 | |
Cytospire Therapeutics
|
Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | |
R1 Therapeutics
|
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M / Series A / Mar 17, 2026 | |
Addition Therapeutics
|
Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovativemethods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies. | $100M / Series A / Dec 17, 2025 | |
Iambic
|
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | |
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $115M / Series C / Aug 27, 2025 | |
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 | |
Atsena Therapeutics
|
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $150M / Series C / Apr 02, 2025 | |
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | |
Timberlyne Therapeutics
|
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company that develops and commercializes revolutionary medicines for autoimmune illnesses. The company utilizes its team's experience in drug development to secure top-tier assets focused on promising targets, and implementing them in disease areas with considerable unmet needs. | $180M / Series A / Jan 09, 2025 | |
| See all 173 investments → | |||
Co-Investors
MPM Capital
14 deals together
OrbiMed
13 deals together
Atlas Venture
12 deals together
Omega Funds
12 deals together
OUP (Osage University Partners)
12 deals together
SR One
11 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Abingworth invest in?
Abingworth invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 173 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Abingworth's check size?
Abingworth typically joins rounds of $14M–$115M at Series A, $18M–$95M at Series B and $20M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Abingworth participates in.
How do I contact Abingworth?
Public channels for Abingworth include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Abingworth?
The team at Abingworth includes Brian Gallagher (Partner), John Shields (Advisor, Science and Technology) and Quentin Lloyd-Harris (Partner), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
